Cargando…

Case Report: Infectious prophylaxis in hematological malignancies

Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passucci, Mauro, Masucci, Chiara, Paoletti, Francesca, Ielo, Claudia, Costa, Alessandro, Carmosino, Ida, Scalzulli, Emilia, Martelli, Maurizio, Gentile, Giuseppe, Breccia, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604/ https://www.ncbi.nlm.nih.gov/pubmed/37197426 http://dx.doi.org/10.3389/fonc.2023.1163175

Ejemplares similares

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
por: Masucci, Chiara, et al.
Publicado: (2023)

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
por: Scalzulli, Emilia, et al.
Publicado: (2022)

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

1591. Infectious Outcomes of Levofloxacin Prophylaxis in Obese vs. Non-obese Patients with Hematologic Malignancies
por: Kurtti, Amanda, et al.
Publicado: (2018)

American Society of Hematology 2020 Podcast Collection: CML
por: Breccia, Massimo
Publicado: (2021)

American Society of Hematology 2020 Podcast Collection: MPN
por: Breccia, Massimo
Publicado: (2021)

Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol)
por: Malagola, Michele, et al.
Publicado: (2022)

Prophylaxis with levofloxacin: bacterial infections and antimicrobial resistance in hematological malignancies
por: Campos, Claudio Penido
Publicado: (2014)

Chemotherapy-related infectious complications in patients with Hematologic malignancies
por: Rusu, Raluca-Ana, et al.
Publicado: (2018)

Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections
por: Moreno-Sanchez, Francisco, et al.
Publicado: (2022)

Preventing transmission of infectious agents in the pediatric in-patients hematology-oncology setting: what is the role for non-pharmacological prophylaxis?
por: Caselli, Désirée, et al.
Publicado: (2011)

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
por: Neumann, S., et al.
Publicado: (2013)

2113. Infectious endocarditis in patients with hematologic malignancy at the University of Wisconsin
por: Scolarici, Michael J, et al.
Publicado: (2022)

Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
por: Villafuerte-Gutierrez, Paola, et al.
Publicado: (2014)

Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy
por: Ziegler, Matthew, et al.
Publicado: (2019)

The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study
por: Efficace, Fabio, et al.
Publicado: (2021)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
por: Puzzolo, Maria Cristina, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Role of Extracellular Vesicles in Hematological Malignancies
por: Raimondo, Stefania, et al.
Publicado: (2015)

Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy
por: Linder, Kathleen A, et al.
Publicado: (2019)

Pulmonary Infectious Complications in Children with Hematologic Malignancies and Chemotherapy-Induced Neutropenia
por: Voulgaridou, Aikaterini, et al.
Publicado: (2020)

Corrigendum to “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update”
por: Villafuerte-Gutierrez, Paola, et al.
Publicado: (2019)

1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy
por: Ziegler, Matthew, et al.
Publicado: (2018)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
por: Sandherr, Michael, et al.
Publicado: (2015)

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)
por: Classen, Annika Y., et al.
Publicado: (2021)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

‘Leaky gut’ in hematological malignancies()
por: Costa-Lima, Carolina, et al.
Publicado: (2014)

Secondary Antifungal Prophylaxis in Hematological Malignancy Patients with Previous Invasive Fungal Disease: A Retrospective Analysis
por: Liu, Mingjuan, et al.
Publicado: (2014)

2685. Oral Third-Generation Cephalosporins vs. Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients with Hematologic Malignancies
por: DeVoe, Catherine, et al.
Publicado: (2019)

BAL fluid analysis in the identification of infectious agents in patients with hematological malignancies and pulmonary infiltrates
por: Zak, P., et al.
Publicado: (2019)

Early and Late Complications Related to Central Venous Catheters in Hematological Malignancies: a Retrospective Analysis of 1102 Patients
por: Morano, Salvatore Giacomo, et al.
Publicado: (2014)

IL-31, itch and hematological malignancies
por: Di Salvo, Eleonora, et al.
Publicado: (2021)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

Mucorales-Specific T Cells in Patients with Hematologic Malignancies
por: Potenza, Leonardo, et al.
Publicado: (2016)

Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies
por: Raza, Yasharah, et al.
Publicado: (2022)

1542. Infectious Complications in Patients Following Umbilical Cord Blood Transplant (UCBT) for Hematologic Malignancy
por: Linder, Kathleen A, et al.
Publicado: (2018)

Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies
por: Maurer, Stephen M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r8ag47jedli3k96ik0lvifgker